Viridian Therapeutics (STU:1S1) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1S1 Viridian Therapeutics Inc STU:1S1
64 GF Score
Price €20.80
GF Value €1,148.82
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Viridian Therapeutics SpecialCharges?

Special Charges only applies to banks.

STU:1S1
64GF Score
Viridian Therapeutics Inc STU:1S1
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Viridian Therapeutics (STU:1S1) Overvalued in 2026?

Based on GuruFocus' analysis, Viridian Therapeutics stock appears to be undervalued. The current stock price of €20.80 is trading 98.2% below its estimated GF Value™ of €1,148.82. GuruFocus considers Viridian Therapeutics to be Possible Value Trap.

Key valuation signals for STU:1S1:

  • SpecialCharges:
  • GF Value™: €1,148.82 vs. price of €20.80 (98.2% below fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the STU:1S1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viridian Therapeutics Business Description

Other Exchanges VRDN:USA0K1R:UK
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
64GF Score

Get the complete analysis for STU:1S1

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.80
Price
€1,148.82
GF Value